vs
爱彼迎（ABNB）与碧迪（BDX）财务数据对比。点击上方公司名可切换其他公司
碧迪的季度营收约是爱彼迎的1.9倍（$5.3B vs $2.8B），爱彼迎净利率更高（12.3% vs 7.3%，领先5.0%），爱彼迎同比增速更快（12.0% vs -0.4%），过去两年爱彼迎的营收复合增速更高（13.9% vs 2.0%）
爱彼迎是全球知名的旅行住宿及体验共享平台，成立于2007年，2010年正式启用现名。平台连接全球各地的房东与旅客，用户可通过网页或移动端预订私人客房、普通住宅、度假屋等多元住宿，也可报名参与当地特色体验项目，是共享经济领域的代表性企业。
碧迪（Becton Dickinson）是美国跨国医疗科技企业，核心业务包括研发、生产及销售医用器械、仪器系统与试剂产品，同时在特定领域提供专业咨询及数据分析服务，业务覆盖全球多国，在全球医疗技术领域具备领先地位。
ABNB vs BDX — 直观对比
营收规模更大
BDX
是对方的1.9倍
$2.8B
营收增速更快
ABNB
高出12.4%
-0.4%
净利率更高
ABNB
高出5.0%
7.3%
两年增速更快
ABNB
近两年复合增速
2.0%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $2.8B | $5.3B |
| 净利润 | $341.0M | $382.0M |
| 毛利率 | 82.5% | 45.9% |
| 营业利润率 | 9.7% | 10.5% |
| 净利率 | 12.3% | 7.3% |
| 营收同比 | 12.0% | -0.4% |
| 净利润同比 | -26.0% | 24.0% |
| 每股收益（稀释后） | — | $1.34 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABNBBDX
| Q4 25 | $2.8B | $5.3B | ||
| Q3 25 | $4.1B | $5.9B | ||
| Q2 25 | $3.1B | $5.5B | ||
| Q1 25 | $2.3B | $5.3B | ||
| Q4 24 | $2.5B | $5.2B | ||
| Q3 24 | $3.7B | $5.4B | ||
| Q2 24 | $2.7B | $5.0B | ||
| Q1 24 | $2.1B | $5.0B |
净利润ABNBBDX
| Q4 25 | $341.0M | $382.0M | ||
| Q3 25 | $1.4B | $493.0M | ||
| Q2 25 | $642.0M | $574.0M | ||
| Q1 25 | $154.0M | $308.0M | ||
| Q4 24 | $461.0M | $303.0M | ||
| Q3 24 | $1.4B | $400.0M | ||
| Q2 24 | $555.0M | $487.0M | ||
| Q1 24 | $264.0M | $537.0M |
毛利率ABNBBDX
| Q4 25 | 82.5% | 45.9% | ||
| Q3 25 | 86.6% | 47.5% | ||
| Q2 25 | 82.4% | 47.8% | ||
| Q1 25 | 77.7% | 42.8% | ||
| Q4 24 | 82.8% | 43.2% | ||
| Q3 24 | 87.5% | 45.7% | ||
| Q2 24 | 81.6% | 46.2% | ||
| Q1 24 | 77.6% | 45.7% |
营业利润率ABNBBDX
| Q4 25 | 9.7% | 10.5% | ||
| Q3 25 | 39.7% | 11.8% | ||
| Q2 25 | 19.8% | 16.0% | ||
| Q1 25 | 1.7% | 10.4% | ||
| Q4 24 | 17.3% | 8.8% | ||
| Q3 24 | 40.9% | 11.4% | ||
| Q2 24 | 18.1% | 12.1% | ||
| Q1 24 | 4.7% | 14.5% |
净利率ABNBBDX
| Q4 25 | 12.3% | 7.3% | ||
| Q3 25 | 33.6% | 8.4% | ||
| Q2 25 | 20.7% | 10.4% | ||
| Q1 25 | 6.8% | 5.8% | ||
| Q4 24 | 18.6% | 5.9% | ||
| Q3 24 | 36.7% | 7.4% | ||
| Q2 24 | 20.2% | 9.8% | ||
| Q1 24 | 12.3% | 10.6% |
每股收益（稀释后）ABNBBDX
| Q4 25 | — | $1.34 | ||
| Q3 25 | — | $1.71 | ||
| Q2 25 | — | $2.00 | ||
| Q1 25 | — | $1.07 | ||
| Q4 24 | — | $1.04 | ||
| Q3 24 | — | $1.37 | ||
| Q2 24 | — | $1.68 | ||
| Q1 24 | — | $1.85 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $11.0B | $740.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $8.2B | $25.3B |
| 总资产 | $22.2B | $54.8B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ABNBBDX
| Q4 25 | $11.0B | $740.0M | ||
| Q3 25 | $11.7B | $641.0M | ||
| Q2 25 | $11.4B | $735.0M | ||
| Q1 25 | $11.5B | $667.0M | ||
| Q4 24 | $10.6B | $711.0M | ||
| Q3 24 | $11.3B | $1.7B | ||
| Q2 24 | $11.3B | $4.5B | ||
| Q1 24 | $11.1B | $2.3B |
股东权益ABNBBDX
| Q4 25 | $8.2B | $25.3B | ||
| Q3 25 | $8.6B | $25.4B | ||
| Q2 25 | $7.8B | $25.5B | ||
| Q1 25 | $7.9B | $25.2B | ||
| Q4 24 | $8.4B | $25.2B | ||
| Q3 24 | $8.5B | $25.9B | ||
| Q2 24 | $8.0B | $25.9B | ||
| Q1 24 | $7.9B | $25.6B |
总资产ABNBBDX
| Q4 25 | $22.2B | $54.8B | ||
| Q3 25 | $23.1B | $55.3B | ||
| Q2 25 | $27.0B | $54.9B | ||
| Q1 25 | $25.1B | $54.5B | ||
| Q4 24 | $21.0B | $54.7B | ||
| Q3 24 | $22.2B | $57.3B | ||
| Q2 24 | $26.3B | $55.6B | ||
| Q1 24 | $24.5B | $54.2B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $526.0M | $657.0M |
| 自由现金流经营现金流 - 资本支出 | — | $549.0M |
| 自由现金流率自由现金流/营收 | — | 10.5% |
| 资本支出强度资本支出/营收 | — | 2.1% |
| 现金转化率经营现金流/净利润 | 1.54× | 1.72× |
| 过去12个月自由现金流最近4个季度 | — | $2.6B |
8季度趋势，按日历期对齐
经营现金流ABNBBDX
| Q4 25 | $526.0M | $657.0M | ||
| Q3 25 | $1.4B | $1.4B | ||
| Q2 25 | $975.0M | $1.2B | ||
| Q1 25 | $1.8B | $164.0M | ||
| Q4 24 | $466.0M | $693.0M | ||
| Q3 24 | $1.1B | $1.2B | ||
| Q2 24 | $1.1B | $1.3B | ||
| Q1 24 | $1.9B | $514.0M |
自由现金流ABNBBDX
| Q4 25 | — | $549.0M | ||
| Q3 25 | — | $1.0B | ||
| Q2 25 | — | $1.0B | ||
| Q1 25 | — | $35.0M | ||
| Q4 24 | — | $588.0M | ||
| Q3 24 | — | $882.0M | ||
| Q2 24 | — | $1.1B | ||
| Q1 24 | — | $380.0M |
自由现金流率ABNBBDX
| Q4 25 | — | 10.5% | ||
| Q3 25 | — | 17.0% | ||
| Q2 25 | — | 19.0% | ||
| Q1 25 | — | 0.7% | ||
| Q4 24 | — | 11.4% | ||
| Q3 24 | — | 16.2% | ||
| Q2 24 | — | 22.4% | ||
| Q1 24 | — | 7.5% |
资本支出强度ABNBBDX
| Q4 25 | — | 2.1% | ||
| Q3 25 | — | 6.0% | ||
| Q2 25 | — | 3.2% | ||
| Q1 25 | — | 2.4% | ||
| Q4 24 | — | 2.0% | ||
| Q3 24 | — | 5.4% | ||
| Q2 24 | — | 3.6% | ||
| Q1 24 | — | 2.7% |
现金转化率ABNBBDX
| Q4 25 | 1.54× | 1.72× | ||
| Q3 25 | 0.99× | 2.75× | ||
| Q2 25 | 1.52× | 2.12× | ||
| Q1 25 | 11.62× | 0.53× | ||
| Q4 24 | 1.01× | 2.29× | ||
| Q3 24 | 0.79× | 2.94× | ||
| Q2 24 | 1.89× | 2.66× | ||
| Q1 24 | 7.28× | 0.96× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ABNB
| North America | $1.1B | 41% |
| EMEA | $930.0M | 33% |
| Latin America | $351.0M | 13% |
| Other | $351.0M | 13% |
BDX
| Other | $2.8B | 53% |
| Medication Management Solutions | $678.0M | 13% |
| Urologyand Critical Care | $339.0M | 6% |
| Surgery | $310.0M | 6% |
| Peripheral Intervention | $265.0M | 5% |
| Specimen Management | $245.0M | 5% |
| Advanced Patient Monitoring | $178.0M | 3% |
| Diagnostic Solutions | $176.0M | 3% |
| Bio Pharma Systems | $150.0M | 3% |
| Biosciences | $124.0M | 2% |
